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We appreciate Candido-dos-Reis’s feedback and agree that the
variable “oncology centre,”1 which we defined as “tertiary
referral centres with a specific gynaecology oncology unit,” is
unconventional.2 We anticipated that it would raise some
questions. The variable was included because it is a predictor
of prior risk of malignancy and because it is still predictive after
controlling for the other eight patient specific predictor variables.
It is the weakest of the nine ADNEX predictor variables,
suggesting that patient specific predictors explain most but not
all of the differences in outcomes between oncology centres
and other hospitals. In practice this variable is easy to use,
because clinicians have to decide only once in what type of
centre they work.
The prevalence of adnexal masses is much higher in ultrasound
units linked to specialised gynaecological oncology centres than
in regional hospitals. This is because patients with more
suspicious looking masses are referred for assessment and
treatment in specialised centres. We agree that symptoms may
add important information and that women with symptoms
suspicious of ovarian cancer are more likely to be referred to
cancer centres. However, the IOTA study started in 1999 and
indices to report symptoms were developed more recently, so
we don’t know whether patients in oncology centres present
with different symptoms and whether the presence or absence
of certain symptoms could replace the variable “oncology
centre.” We are examining symptoms as part of phase 5 of our
study and should be able to answer this question once this is
completed.
We found that almost all “oncology centres” have a more than
22% prevalence of cancer in adnexal masses, whereas this is
below 22% for other centres.2 However, we took the view that
clinicians will always know their type of centre but might not
know the prevalence of cancer in the masses seen in their
department.
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